The EBV-MS paradigm: beyond molecular mimicry toward new therapeutic strategies
Acta Biochimica et Biophysica Sinica · 2026
DOI: 10.3724/abbs.2026026 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Biochimica et Biophysica Sinica, 2026. Verfasst von Huating Xie und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou 350122, China. Hauptthemen laut MEDLINE: Molecular Mimicry, Herpesvirus 4, Human, Multiple Sclerosis, Epstein-Barr Virus Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 70 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou 350122, China.
- Department of Medical Microbiology, Fujian Key Laboratory of Tumor Microbiology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China.
- Department of Gastroenterology, 900th Hospital of Joint Logistics Support Force, Fujian Medical University, Fuzhou 350025, China.
Zitieren
APA
Xie, H., Huang, W., Li, W., Lai, S., Lin, Z., Zhong, R., Wang, W., Lin, X., & Xu, Z. (2026). The EBV-MS paradigm: beyond molecular mimicry toward new therapeutic strategies. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2026026
Vancouver
Xie H, Huang W, Li W, Lai S, Lin Z, Zhong R, et al. The EBV-MS paradigm: beyond molecular mimicry toward new therapeutic strategies. Acta Biochimica et Biophysica Sinica. 2026. doi:10.3724/abbs.2026026
BibTeX
@article{Xie2026,
author = {Xie, Huating and Huang, Weidong and Li, Weikun and Lai, Shiying and Lin, Zhiqun and Zhong, Rongqing and Wang, Wen and Lin, Xu and Xu, Zhaowei},
title = {The EBV-MS paradigm: beyond molecular mimicry toward new therapeutic strategies},
journal = {Acta Biochimica et Biophysica Sinica},
year = {2026},
doi = {10.3724/abbs.2026026}
}
EUVIMED